KNSA

News Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

14d ago

Insider trade Sale by John F. Paolini (CHIEF MEDICAL OFFICER)

27d ago

Insider trade Sale by Sanj K Patel (CHAIRMAN & CEO)

31d ago

Insider trade Sale by Sanj K Patel (CHAIRMAN & CEO)

32d ago

Insider trade Sale by Barry D Quart

33d ago

News Kiniksa hits 52-week high as Regeneron-partnered lead product drives Q1 beat

35d ago

SEC filing KNSA Reports $214.3M Q1 Revenue, $22.6M Net Income, Raises 2026 ARCALYST Guidance to $930-945M

35d ago

Insider trade Sale by Michael R Megna (CHIEF ACCOUNTING OFFICER)

49d ago

Insider trade Sale by Ross Moat (CHIEF OPERATING OFFICER)

49d ago

Insider trade Sale by Sanj K Patel (CHAIRMAN & CEO)

54d ago

Insider trade Sale by Ross Moat (CHIEF OPERATING OFFICER)

54d ago

Insider trade Sale by Barry D Quart

54d ago

Insider trade Sale by Mark Ragosa (CHIEF FINANCIAL OFFICER)

82d ago

Insider trade Sale by John F. Paolini (CHIEF MEDICAL OFFICER)

89d ago

News Kiniksa Pharmaceuticals International, plc Q4 2025 Earnings Preview

99d ago

Insider trade Sale by Barry D Quart

104d ago

Insider trade Sale by Barry D Quart

104d ago

News Is Estée Lauder (EL) a Resilient Stock?

125d ago

News Kiniksa Pharmaceuticals sees ARCALYST net product revenue between $900M-$920M for 2026

141d ago